135 related articles for article (PubMed ID: 37072360)
1. Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK).
Hayoz S; Kasenda B; Schenker AL; Kopp C; Schär S; Thürlimann B; von Moos R; Pless M
BMJ Open; 2023 Apr; 13(4):e068490. PubMed ID: 37072360
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study.
Amstutz A; Schandelmaier S; Frei R; Surina J; Agarwal A; Olu KK; Alturki R; Von Niederhäusern B; Von Elm E; Briel M
BMJ Open; 2017 Aug; 7(7):e016216. PubMed ID: 28765131
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Impact of study outcome on submission and acceptance metrics for peer reviewed medical journals: six year retrospective review of all completed GlaxoSmithKline human drug research studies.
Evoniuk G; Mansi B; DeCastro B; Sykes J
BMJ; 2017 Apr; 357():j1726. PubMed ID: 28432051
[No Abstract] [Full Text] [Related]
5. Time to publication of oncology trials and why some trials are never published.
Chapman PB; Liu NJ; Zhou Q; Iasonos A; Hanley S; Bosl GJ; Spriggs DR
PLoS One; 2017; 12(9):e0184025. PubMed ID: 28934243
[TBL] [Abstract][Full Text] [Related]
6. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
Khunger M; Rakshit S; Hernandez AV; Pasupuleti V; Glass K; Galsky MD; Grivas P
Oncologist; 2018 Dec; 23(12):1494-1499. PubMed ID: 30068783
[TBL] [Abstract][Full Text] [Related]
7. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.
Peters GW; Tao W; Wei W; Miccio JA; Jethwa KR; Cecchini M; Johung KL
Oncologist; 2021 Aug; 26(8):660-667. PubMed ID: 33728733
[TBL] [Abstract][Full Text] [Related]
8. General characteristics and reasons for the discontinuation of drug clinical trials in mainland China.
Huo BN; Ai ML; Jia YT; Liu Y; Wang Y; Yin NG; Song L
BMC Med Res Methodol; 2021 Nov; 21(1):246. PubMed ID: 34773983
[TBL] [Abstract][Full Text] [Related]
9. Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis.
Speich B; Gryaznov D; Busse JW; Gloy VL; Lohner S; Klatte K; Taji Heravi A; Ghosh N; Lee H; Mansouri A; Marian IR; Saccilotto R; Nury E; Kasenda B; Ojeda-Ruiz E; Schandelmaier S; Tomonaga Y; Amstutz A; Pauli-Magnus C; Bischoff K; Wollmann K; Rehner L; Meerpohl JJ; Nordmann A; Wong J; Chow N; Hong PJ; Mc Cord-De Iaco K; Sricharoenchai S; Agarwal A; Schwenkglenks M; Hemkens LG; von Elm E; Copsey B; Griessbach AN; Schönenberger C; Mertz D; Blümle A; von Niederhäusern B; Hopewell S; Odutayo A; Briel M
PLoS Med; 2022 Apr; 19(4):e1003980. PubMed ID: 35476675
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials.
Huang H; Chen Z; Zhu M; Deng X; Yu L; Weng H; Yao Y; Hong H; Fang X; Wang Z; Tian Y; Huang H; Lin T
Oral Oncol; 2024 Jan; 148():106656. PubMed ID: 38065019
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, characteristics, and publication of discontinued randomized trials.
Kasenda B; von Elm E; You J; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Meerpohl JJ; Stegert M; Tikkinen KA; Neumann I; Carrasco-Labra A; Faulhaber M; Mulla SM; Mertz D; Akl EA; Bassler D; Busse JW; Ferreira-González I; Lamontagne F; Nordmann A; Gloy V; Raatz H; Moja L; Rosenthal R; Ebrahim S; Schandelmaier S; Xin S; Vandvik PO; Johnston BC; Walter MA; Burnand B; Schwenkglenks M; Hemkens LG; Bucher HC; Guyatt GH; Briel M
JAMA; 2014 Mar; 311(10):1045-51. PubMed ID: 24618966
[TBL] [Abstract][Full Text] [Related]
14. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
[TBL] [Abstract][Full Text] [Related]
15. Insufficient recruitment and premature discontinuation of clinical trials in Switzerland: qualitative study with trialists and other stakeholders.
Briel M; Elger B; von Elm E; Satalkar P
Swiss Med Wkly; 2017; 147():w14556. PubMed ID: 29185240
[TBL] [Abstract][Full Text] [Related]
16. Rates of Discontinuation and Nonpublication of Head and Neck Cancer Randomized Clinical Trials.
Johnson AL; Fladie I; Anderson JM; Lewis DM; Mons BR; Vassar M
JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):176-182. PubMed ID: 31876933
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history.
Mooney LA; Fay L
BMJ Open; 2016 Jul; 6(7):e012362. PubMed ID: 27431904
[TBL] [Abstract][Full Text] [Related]
18. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications.
Alturki R; Schandelmaier S; Olu KK; von Niederhäusern B; Agarwal A; Frei R; Bhatnagar N; Hooft L; von Elm E; Briel M
J Clin Epidemiol; 2017 Jan; 81():56-63. PubMed ID: 27614277
[TBL] [Abstract][Full Text] [Related]
19. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands.
van den Bogert CA; Souverein PC; Brekelmans CTM; Janssen SWJ; Koëter GH; Leufkens HGM; Bouter LM
J Clin Epidemiol; 2017 Aug; 88():140-147. PubMed ID: 28487159
[TBL] [Abstract][Full Text] [Related]
20. Publication status of contemporary oncology randomised controlled trials worldwide.
Chen YP; Liu X; Lv JW; Li WF; Zhang Y; Guo Y; Lin AH; Sun Y; Mao YP; Ma J
Eur J Cancer; 2016 Oct; 66():17-25. PubMed ID: 27522246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
